Oana Spataru, MD
Vascular Neurology · Walnut Creek, CANPI 1518153824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. UCB, Inc. accounts for 92.8% of it on its own, with 2 other manufacturers making up the rest.
Across 38 payments — averaging $33.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$1K
- AstraZeneca$69
- Eisai Inc.$22
What the payments were for
- Food & beverage$1,274100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 34 | $1,182 |
| AstraZeneca | 3 | $69 |
| Eisai Inc. | 1 | $22 |
How this compares
$1,274 in reported general payments places this provider in the 65th percentile of 58 vascular neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $63,123 |
| Lacosamide | 75 | $5,907 |
| Levetiracetam | 104 | $3,891 |
| Baclofen | 49 | $1,683 |
| Gabapentin | 72 | $1,315 |
| Labetalol Hcl | 22 | $935 |
| Memantine Hcl | 21 | $759 |
| Quetiapine Fumarate | 25 | $569 |
| Amlodipine Besylate | 56 | $455 |
| Mirtazapine | 16 | $419 |
| Atorvastatin Calcium | 58 | $379 |
| Lisinopril | 26 | $311 |
| Duloxetine Hcl | 11 | $308 |
| Risperidone | 13 | $253 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 13 | $209 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Walnut Creek
- Gregory AlbersStanford$415K
- Chitra VenkatasubramanianStanford$260K
- Shuichi SuzukiArcadia$126K
- Royya ModirSan Diego$113K
- Maarten LansbergStanford$86K
- Muhammad TaqiPalm Springs$77K
- Ashish NandaFullerton$66K
- Andrew XavierMountain View$46K
- Sarah LeeStanford$35K
- May NourLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.